Sirigen, a Ringwood, UK-based medical technology company, has raised £3.83m in a new financing round.
Investors include existing shareholders Seraphim Capital and Oxford Capital Partners, and new backers IQ Capital, the National Endowment for Science, Technology and the Arts (NESTA) and YFM Private Equity.
The company intends to use the new capital to commercialize its “high sensitivity flourescence” technology, which is designed to enhance the performance of diagnostic tools used to analyse and manage diseases such as HIV and leukaemia.
In conjunction with the funding, Ivan Griffin of NESTA and Max Bautin of IQ Capital, have joined the Sirigen’s board. Arthur Cole, who previously held senior roles at Visible Genetics and Pharmacia Biotech, join as an additional non-executive chairman.
The company also announced that David Evans will serve as new Chairman. Mr Evans was chairman of molecular diagnostics company DxS that was recently acquired by Qiagen for up to $130m (£80m).
Sirigen also operates a US subsidiary in San Diego, CA.